This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ

May 8th, 2019

Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS.

Breast cancer is the most common cancer in the UK and is responsible for thousands of deaths each year. Ductal carcinoma in situ (DCIS) is a common type of breast cancer that does not spread, but can mutate over time to become metastatic cancer. DCIS is normally removed surgically, however there is a risk of recurrence after treatment, and it is currently difficult to predict this risk when assessing patients.

This study looked at over 860 patients with DCIS to find ways of predicting whether DCIS is likely to return after surgery or develop into metastatic disease. We found that HER2 expression can predict DCIS recurrence and progression.

By screening DCIS patients for HER2, we could ensure that high-risk patients are offered treatments to minimize the chance of recurrence or spread, while lower risk DCIS patients could avoid unnecessary treatment.

More information:
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution, British Journal of Cancer, DOI: 10.1038/s41416-019-0436-3

Provided by Cancer Research UK

Citation: The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ (2019, May 8) retrieved 10 May 2024 from https://sciencex.com/wire-news/318740777/the-clinical-and-biological-significance-of-her2-over-expression.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.